Predictive Value of Nasal Nitric Oxide and Serum NOS2 Levels in the Efficacy of Subcutaneous Immunotherapy in Pediatric Patients with Allergic Rhinitis
Table 4
Demographics and clinical characteristics of two groups.
Variables
Effective group ()
Ineffective group ()
value
Sex
0.016
Male
23 (36.5%)
14 (66.7%)
Female
40 (63.5%)
7 (33.3%)
Age, years
0.327
BMI, kg/m2
0.356
Smoking
12 (19.0%)
2 (9.5%)
0.310
Alcohol consumption
9 (14.3%)
0 (0.0%)
0.067
nNO, ppb
0.008
Serum NOS2(IU/ml)
<0.001
Disease duration, years
0.342
Allergic comorbidities
AS
14 (22.2%)
3 (14.3%)
0.443
AC
9 (14.3%)
4 (19.0%)
0.601
Baseline VAS
0.807
Baseline TNSS
0.506
BMI: body mass index; nNO: nasal nitric oxide; ppb: parts per billion; AS: allergic asthma; AC: allergic conjunctivitis; TNSS: total nasal symptom score; VAS: visual analogue scale.
